Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
9
PTIX Quote, Financials, Valuation and Earnings
Last price:
$3.53
Seasonality move
:
1.79%
Day range:
$3.40 - $3.52
52-week range:
$2.35 - $15.54
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.13x
P/B ratio:
1.61x
Volume:
106K
Avg. volume:
188.9K
1-year change:
-65.77%
Market cap:
$2M
Revenue:
--
EPS (TTM):
-$13.11
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Protagenic Therapeutics has 6392.75% upside to fair value with a price target of -- per share.
PTIX vs. S&P 500
-
Over the past 5 trading days, Protagenic Therapeutics has underperformed the S&P 500 by -9.98% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Protagenic Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Protagenic Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Protagenic Therapeutics reported revenues of --.
Earnings Growth
-
Protagenic Therapeutics earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Protagenic Therapeutics reported earnings per share of -$2.75.
Enterprise value:
1.2M
EV / Invested capital:
--
Price / LTM sales:
0.13x
EV / EBIT:
--
EV / Revenue:
0.17x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.32x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$3M | -$5.5M | -$5.4M | -$1.7M | -$1.4M | |
| EBITDA | -$2.8M | -$5.9M | -$5.2M | -$1.7M | -$1.4M | |
| Diluted EPS | -$9.38 | -$19.16 | -$13.11 | -$5.44 | -$2.75 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $196.1K | $9.8M | $7.7M | $2.5M | $928.2K | |
| Total Assets | $196.1K | $9.8M | $7.7M | $2.6M | $988.7K | |
| Current Liabilities | $651K | $783.6K | $1.3M | $446.1K | $1.1M | |
| Total Liabilities | $2.2M | $1.1M | $1.3M | $446.1K | $1.1M | |
| Total Equity | -$2M | $8.7M | $6.4M | $2.1M | -$88.3K | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.9M | -$5M | -$3.6M | -$1.7M | -$1.1M | |
| Cash From Investing | $1.5M | $5.7M | $1.6M | $1.2M | -- | |
| Cash From Financing | -- | -- | $2.1M | -- | $102.5K | |
| Free Cash Flow | -$1.9M | -$5M | -$3.6M | -$1.7M | -$1.1M | |
PTIX
Sector
Market Cap
$2M
$34.4M
Price % of 52-Week High
22.2%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-65.77%
-37.36%
Beta (5-Year)
0.354
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.57
200-day SMA
Sell
Level
$5.61
Bollinger Bands (100)
Sell
Level
2.82 - 4.8
Chaikin Money Flow
Buy
Level
93K
20-day SMA
Sell
Level
$3.58
Relative Strength Index (RSI14)
Sell
Level
45.65
ADX Line
Buy
Level
15.14
Williams %R
Buy
Level
-81.3187
50-day SMA
Sell
Level
$3.85
MACD (12, 26)
Buy
Level
0.97
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Sell
Level
-418.3K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Stock Forecast FAQ
In the current month, PTIX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PTIX average analyst price target in the past 3 months is --.
-
Where Will Protagenic Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Protagenic Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Protagenic Therapeutics?
Analysts are divided on their view about Protagenic Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Protagenic Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Protagenic Therapeutics's Price Target?
The price target for Protagenic Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PTIX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Protagenic Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PTIX?
You can purchase shares of Protagenic Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Protagenic Therapeutics shares.
-
What Is The Protagenic Therapeutics Share Price Today?
Protagenic Therapeutics was last trading at $3.53 per share. This represents the most recent stock quote for Protagenic Therapeutics. Yesterday, Protagenic Therapeutics closed at $3.45 per share.
-
How To Buy Protagenic Therapeutics Stock Online?
In order to purchase Protagenic Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
